Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
J Am Coll Cardiol. 2011 Sep 13;58(12):1231-7. doi: 10.1016/j.jacc.2011.05.046.
The aim of this study was to examine whether Rho-kinase activity is systemically enhanced in patients with vasospastic angina (VSA) and, if so, whether a noninvasive diagnostic method could be developed to improve practice.
The activated Rho-kinase pathway plays a central role in the molecular mechanism of coronary vasospasm in animal models and patients with VSA. Recently, it has been reported that Rho-kinase activity in circulating leukocytes is associated with various diseases.
Fifty-three consecutive patients with chest pain who underwent acetylcholine provocation testing for coronary spasm were examined. Patients were divided into 2 groups depending on their response to the test: VSA (n = 33) and non-VSA (n = 20) groups. Venous blood samples were collected to measure Rho-kinase activity in circulating neutrophils, determined by the extent of phosphorylation of myosin-binding subunit (MBS), a substrate of Rho-kinase.
Rho-kinase activity was significantly higher in the VSA group than in the non-VSA group (phosphorylated MBS/total MBS ratio 1.33 ± 0.37 vs. 0.95 ± 0.22, p < 0.001). In the VSA group, no correlation was noted between Rho-kinase activity and high-sensitivity C-reactive protein, smoking, or accumulated number of coronary risk factors. After the 3-month medical treatment, Rho-kinase activity in the VSA group was significantly decreased to 1.08 ± 0.31 (p < 0.001). On receiver-operating characteristic curve analysis, a phosphorylated MBS ratio of 1.18 was identified as the best cutoff level to predict the diagnosis of VSA.
These results indicate that Rho-kinase activity in circulating neutrophils is enhanced in patients with VSA and may be a useful biomarker for diagnosis and disease activity assessment of the vasospastic disorder.
本研究旨在探讨血管痉挛性心绞痛(VSA)患者是否存在全身性 Rho 激酶活性增强,如果存在,是否可以开发出一种非侵入性诊断方法来改善临床实践。
激活的 Rho 激酶通路在动物模型和 VSA 患者的冠状动脉痉挛的分子机制中发挥核心作用。最近有报道称,循环白细胞中的 Rho 激酶活性与各种疾病相关。
对 53 例因胸痛而行乙酰胆碱激发试验以检测冠脉痉挛的连续患者进行了检查。根据试验结果将患者分为 2 组:VSA 组(n = 33)和非 VSA 组(n = 20)。采集静脉血样以测量循环中性粒细胞中的 Rho 激酶活性,通过 Rho 激酶的底物肌球蛋白结合亚单位(MBS)的磷酸化程度来确定。
VSA 组的 Rho 激酶活性明显高于非 VSA 组(磷酸化 MBS/总 MBS 比值 1.33 ± 0.37 对 0.95 ± 0.22,p < 0.001)。在 VSA 组中,Rho 激酶活性与高敏 C 反应蛋白、吸烟或累积的冠状动脉危险因素数量之间无相关性。经过 3 个月的药物治疗后,VSA 组的 Rho 激酶活性显著降低至 1.08 ± 0.31(p < 0.001)。在受试者工作特征曲线分析中,1.18 的磷酸化 MBS 比值被确定为预测 VSA 诊断的最佳截断值。
这些结果表明,VSA 患者循环中性粒细胞中的 Rho 激酶活性增强,可能是诊断和评估血管痉挛性疾病活动的有用生物标志物。